Global Biosimilars Monoclonal Antibodies Market Set To Grow To $5.9bn By 2023

02 August 2018
Pharma

Visiongain’ has launched a new pharma report Global Biosimilar Monoclonal Antibodies Forecast 2018-2028: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab

Biosimilar monoclonal antibodies (mAbs) form an emerging sector in pharmaceuticals. As patents for some of the industry’s top-selling biological drugs (biologics) expire, companies have chosen to invest in the development of biosimilars. The result is an R&D pipeline holding at least 86 biosimilar mAb candidates. Emerging markets with less stringent regulatory processes, such as India and Russia, dominated shares of the market in 2017. However, in addition to China, the more developed markets of the US and the EU5 will increase their market shares throughout the forecast period as patents expire on the originator products.

The lead analyst of the report commented “The biosimilar mAbs market will face challenges posed by competition from biobetters and a lack of confidence of some clinicians in biosimilar interchangeability. However, these challenges will be overcome owing to the high demand worldwide for affordable biological drugs, especially therapeutic monoclonal antibodies. Visiongain expects governmental policy to increase preferences for the use of biosimilars mAbs over branded ones as healthcare budgets become increasingly strained. Biosimilar mAbs will therefore have an important, rising role to play in healthcare systems from 2016 to 2028.”

Leading companies featured in the report include BIOCAD, Biocon, BioXpress, Celltrion, Coherus Biosciences, Gene Techno Science, Genor Biopharma, Harvest Moon, Hospira, Mabion, Pfizer, Samsung Bioepsis

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

“Global Rare Disease Drugs market set to grow to $257bn by 2024” says new Visiongain report

It is difficult to investigate rare diseases as the pool of patients is very small and often results in inadequate clinical knowledge.

01 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever